TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01
| Regulation FD Disclosure. |
Tonix Pharmaceuticals Holding Corp. (the Company) intends to
utilize an updated investor presentation to conduct meetings with
investors, stockholders and analysts and at investor conferences,
and which the Company intends to place on its website, which may
contain non-public information.A copy of the presentation is
filed as Exhibit 99.01.
The information contained in Item 7.01 of this Current Report on
Form 8-K, including Exhibit 99.01, is furnished to, and shall not
be deemed to be filed for the purposes of, Section 18 of the
Securities Exchange Act of 1934, as amended, or otherwise subject
to the liabilities of that section.The information contained in
Item 7.01 of this Current Report shall not be incorporated by
reference into any registration statement or any other document
filed to the Securities Act of 1933, as amended, except as
otherwise expressly stated in such filing.By filing this Current
Report on Form 8-K and furnishing the information contained in
this Item 7.01, including Exhibit 99.01, the Company makes no
admission as to the materiality of any such information that it
is furnishing.
| Item 9.01 | Financial Statements and Exhibits. |
| (d) | Exhibits. |
| 99.01 | Corporate Presentation by the Company for January 2017* |
* Furnished herewith.
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Recent Trading Information
TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) closed its last trading session down -0.005 at 0.470 with 1,775,819 shares trading hands.
